Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
38.76
+0.17 (0.44%)
At close: Oct 30, 2026, 4:00 PM EDT
38.63
-0.13 (-0.34%)
After-hours: Oct 30, 2026, 7:36 PM EDT
HRMY Revenue
Harmony Biosciences Holdings had revenue of $261.28M in the quarter ending June 30, 2026, with 30.32% growth. This brings the company's total for the last twelve months to $959.90M, up 24.25% year-over-year. In the year 2025, Harmony Biosciences Holdings had annual revenue of $868.45M with 21.51% growth. That makes Harmony Biosciences Holdings the 7,812th largest company in the world by revenue and 1,818th in the United States.
Revenue (ttm)
$959.90M
Revenue Growth
+24.25%
P/S Ratio
2.35
Revenue / Employee
$3,276,102
Employees
293
Market Cap
2.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 868.45M | 153.72M | 21.51% |
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | 6.00M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Aurinia Pharmaceuticals | 321.74M |
| Xencor | 104.97M |
| Recursion Pharmaceuticals | 54.86M |
| NewAmsterdam Pharma Company | 7.12M |
| Immunome | 4.02M |
| Celldex Therapeutics | 158.00K |
HRMY News
- 3 days ago - Harmony Biosciences price target lowered to $49 from $51 at Mizuho - TheFly
- 10 days ago - Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences - Barrons
- 12 days ago - Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 17 days ago - Harmony Biosciences initiated with a Buy at Ladenburg - TheFly
- 19 days ago - Mizuho positive on Harmony Biosciences CEO transition - TheFly
- 20 days ago - Harmony Biosciences CEO Jeffrey Dayno to retire, Peter Anastasiou to succeed - TheFly
- 4 weeks ago - Harmony Biosciences price target raised to $42 from $39 at Deutsche Bank - TheFly
- 4 weeks ago - Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - GlobeNewsWire